An observational study in End Stage Liver DIsease and Liver Failure, sponsored by Bridge to Life Ltd.. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Bridge to Life Ltd. · Observational
Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.
Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 2nd largest by planned enrollment of the 18 observational ones that give a count, is one of 2 that started in 2026, is one of 18 observational ones, reaches primary completion later than 11 of the 14 other live ones, and was the 66th registered.
154 studies on the registry are indexed under End Stage Liver Disease; 30 are open to participants now.
Browse End Stage Liver Disease studies →9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Massachusetts General Hospital · Sites in United States
Elizabeth C. Verna · Sites in United States
Mayo Clinic · Sites in United States
Children's Hospital Medical Center, Cincinnati · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 take children under 18; 1 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 1 · Phase 4 5
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 200 across 55 observational studies indexed under End Stage Liver Disease.
Median enrollment 64 across the 48 interventional studies, 132 across the 18 observational. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 66 have an industry lead sponsor. The 10 most frequent:
Bridge to Life Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Bridge to Life Ltd. has 2 studies filed under End Stage Liver Disease — fewer than ten, so there is no comparison to draw.
8 of the studies in End Stage Liver Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803423Johns Hopkins UniversityDissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors | 2026-11-27 |
| NCT04592744University of California, Los AngelesAngiotensin 2 for AKI After OLT | 2026-12 |
| NCT05998330Massachusetts General HospitalLiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease | 2026-12-01 |
| NCT06136221University of PennsylvaniaTesting LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease | 2026-12-30 |
| NCT05205954Massachusetts General HospitalHepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease | 2026-12-31 |
Among the 66 studies in End Stage Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a post-market, multicenter, single-arm, observational registry evaluating real-world use of the VitaSmart HOPE System under standard of care conditions. Clinical data from up to 5000 transplant recipients will be included in the registry at up to 20 U.S. transplant centers. This registry will include clinical data collected retrospectively from medical records of recipients already transplanted before the initiation of the registry and any new recipients of livers that meet donor selection criteria. This registry introduces no contact with the transplant recipient and registry participants will follow standard of care. Data will be collected through up to 5 years of standard of care clinical follow-up.
This registry represents minimal risk to the transplant recipients being studied. The participants included in this registry will have undergone transplant surgery with a deceased donor liver graft that was perfused using the VitaSmart HOPE System, a medical device that is cleared by the Food and Drug Administration (FDA) for commercial use in the U.S. All perfusions of deceased donor liver grafts will be performed in accordance with standard medical practice.
The objectives of this registry is to Evaluate the safety and efficacy of HOPE prior to liver transplantation in real-world clinical settings.
Patients (recipients) undergoing liver transplantation with a deceased donor liver graft that was perfused using the VitaSmart HOPE System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Liver graft accepted for transplant and perfused using the VitaSmart HOPE System
Exclusion Criteria:
Recipients who received a deceased donor liver graft that was perfused using VitaSmart hypothermic oxygenated perfusion therapy.
Device: hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditions
Observational, real-world use of the VitaSmart HOPE System with a donor liver graft under standard of care conditions.
Number of Recipients alive with functioning graft at 1-year post-transplant
Number of Recipients alive with functioning graft at 1-year post-transplant (absence of graft failure or death for liver related reasons)
Time frame: 1-year post-transplant
Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bridge to Life Ltd.